Protagonist Therapeutics, Inc Operating Lease, Right-of-Use Asset, Amortization Expense
Protagonist Therapeutics, Inc (PTGX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $2.07 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2025-02-21
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2024-12-31 was $418.00K, a 28.42% decline year-over-year.
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2024-09-30 was $416.00K, a 28.64% decline year-over-year.
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $651.00K, a 11.47% increase year-over-year.
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $584.00K, a 0.00% change year-over-year.
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for fiscal 2024 was $2.07M, a 11.39% decline from fiscal 2023.
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for fiscal 2023 was $2.33M, a 0.00% change from fiscal 2022.
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.33M, a 19.01% increase from fiscal 2021.
- Protagonist Therapeutics, Inc operating lease, right-of-use asset, amortization expense for fiscal 2021 was $1.96M, a 10.54% increase from fiscal 2020.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $418.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $834.00K derived: sum of 2 quarters · filed 2025-02-21 | $1.49M derived: sum of 3 quarters · filed 2025-02-21 | $2.07M 10-K · filed 2025-02-21 |
| 2024-09-30 | $416.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.07M derived: sum of 2 quarters · filed 2024-11-07 | $1.65M 10-Q · filed 2024-11-07 | $2.23M derived: sum of 4 quarters · filed 2025-02-21 |
| 2024-06-30 | $651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.24M 10-Q · filed 2024-08-06 | $1.82M derived: sum of 3 quarters · filed 2025-02-21 | $2.40M derived: sum of 4 quarters · filed 2025-02-21 |
| 2024-03-31 | $584.00K 10-Q · filed 2024-05-07 | $1.17M derived: sum of 2 quarters · filed 2025-02-21 | $1.75M derived: sum of 3 quarters · filed 2025-02-21 | $2.33M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $1.17M derived: sum of 2 quarters · filed 2025-02-21 | $1.75M derived: sum of 3 quarters · filed 2025-02-21 | $2.33M 10-K · filed 2025-02-21 |
| 2023-09-30 | $583.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.17M derived: sum of 2 quarters · filed 2024-11-07 | $1.75M 10-Q · filed 2024-11-07 | $2.33M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $584.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.17M 10-Q · filed 2024-08-06 | $1.75M derived: sum of 3 quarters · filed 2025-02-21 | $2.33M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $584.00K 10-Q · filed 2024-05-07 | $1.17M derived: sum of 2 quarters · filed 2025-02-21 | $1.75M derived: sum of 3 quarters · filed 2025-02-21 | $2.33M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $1.17M derived: sum of 2 quarters · filed 2025-02-21 | $1.75M derived: sum of 3 quarters · filed 2025-02-21 | $2.33M 10-K · filed 2025-02-21 |
| 2022-09-30 | $583.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.17M derived: sum of 2 quarters · filed 2023-11-02 | $1.75M 10-Q · filed 2023-11-02 | $2.33M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $584.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.17M 10-Q · filed 2023-08-03 | $1.75M derived: sum of 3 quarters · filed 2024-02-27 | $2.24M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $584.00K 10-Q · filed 2023-05-04 | $1.17M derived: sum of 2 quarters · filed 2024-02-27 | $1.66M derived: sum of 3 quarters · filed 2024-02-27 | $2.10M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $584.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.07M derived: sum of 2 quarters · filed 2024-02-27 | $1.52M derived: sum of 3 quarters · filed 2024-02-27 | $1.96M 10-K · filed 2024-02-27 |
| 2021-09-30 | $491.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $934.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.38M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $443.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $887.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $444.00K 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $1.77M 10-K · filed 2023-03-15 | |||
| 2019-12-31 | $1.79M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |